We are a clinical-stage biopharmaceutical
company focused on the development of novel products for the treatment of inner ear disorders. Our most advanced product candidates
are in Phase 3 clinical development. Keyzilen® (AM-101) is being developed for the treatment of acute inner ear tinnitus and
has received fast track designation from the FDA. AM-111 is being developed for the treatment of acute inner ear hearing loss and
has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA. AM-125 is being
developed for the treatment of vestibular disorders. In addition, we are pursuing early stage projects for the treatment of tinnitus
We are a stock corporation organized under
the laws of Switzerland. We began our current operations in 2003.
Our principal office is located at Bahnhofstrasse 21, 6300
Zug, Switzerland, telephone number +41 729 71 94. We maintain a website at www.aurismedical.com where general information about
us is available. Investors can obtain copies of our filings with the Securities and Exchange Commission, or SEC, from this site
free of charge, as well as from the SEC website at www.sec.gov. We are not incorporating the contents of our website into this
Before making a decision to invest in our
securities, you should carefully consider the risks described under “Risk Factors” in the applicable prospectus supplement
and in our then most recent Annual Report on Form 20-F, and in any updates to those risk factors in our reports on Form 6-K incorporated
herein, together with all of the other information appearing or incorporated by reference in this prospectus and any applicable
prospectus supplement, in light of your particular investment objectives and financial circumstances.
Earnings to Fixed Charges
The following table sets forth our ratio
of earnings to fixed charges for each of the periods indicated. You should read this table in conjunction with the consolidated
financial statements and notes incorporated by reference in this prospectus.
Year Ended December 31,
|Ratio of earnings to fixed charges
* Our earnings were
insufficient to cover fixed charges by CHF 673,390, CHF 94,732 and CHF 38,000 for the years ended December 31, 2016, 2015
and 2014, respectively.
For purposes of calculating the ratios in the table above, earnings
consist of net profit/(loss) before income taxes plus fixed charges. Fixed charges consist of rental expenses and cash relevant
Use of Proceeds
Unless otherwise indicated in a prospectus
supplement, the net proceeds from our sale of the securities will be used for general corporate purposes and other business opportunities.
We will not receive any of the proceeds
from the sale of any common shares offered by the selling shareholder.